Melinta THERAPEUTICS
The Antibiotics Company

Post Approval Research & Development

Grant Application

NOTE:

This form contains drop-down fields and should be completed electronically

Please include all required documentation with this application

Principal Investigator Contact Information	
Investigator's Name	
Investigator's Title	
Institution/Organization	
Office Address	
Phone	
Fax	
Email	
Curriculum Vitae (CV)	CV attached, initialed and dated within prior 2 years ◯ CV date: N/A ◯

Melinta THERAPEUTICS
The Antibiotics Company

Post Approval Research & Development

Grant Application

Study Specifications		
Sponsor		
Title of Proposal/Protocol		
Melinta Study Drug		
Study Type (e.g. Phase, in vitro, registry, etc.)	Please specify study type:	If 'Other', please specify:
Design	Number of Arms:	
	Number of Cohorts:	
	Randomized ◯ Yes ◯ No	
	Stratified ◯ Yes ◯ No If 'Yes", please specify type of stratification:	
	Type of control group: If 'Other', please specify:	
	Blinded ◯ Yes ◯ No If 'Yes", please specify type of blind:	

Patient Population (e.g., intracranial hemorrhage patients)		
Number of Sites/Countries	Geographic scope:	
	Total No. Sites:	Total No Countries:
	List <u>All Planned</u> Countries:	
Sample Size	Number of patients to be evaluated across all arms/cohorts:	
	Number of patients within above total to receive Melinta drug/device:	

Deliverables	
Presentations	Describe the intent to present this information at a congress/venue, including: 1) the name of the venue and 2) expected month and/or year of the event.
Publications	Please describe the publication plan for this study, including the name or names of targeted journals.

Melinta THERAPEUTICS
The Antibiotics Company

Post Approval Research & Development

Grant Application

Regulatory & Institutional Review Board/Committee Review Process (IRB, EC, etc.)	
Board/Committee Review *As required per local regulations	What type of board approval will be required for this study?
	If 'Other', please specify:
	How often does the review board or committee meet? Comments:
Regulatory Authority	Will this study be submitted to a Regulatory Authority? ◯ No ◯ Yes
	If this research will be conducted outside of the US, will you need to obtain Regulatory Authority documented approval be required prior to commencement of this study or data collection? ◯ No ◯ Yes ◯ N/A – US only
Requires an IND *Melinta to confirm agreement with this as part of Melinta's internal grants review process	Per Part 21 CFR 312.2, Applicability http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.2 (or other applicable central regulatory registration) Please indicate whether this study will be required to be conducted under an IND.
Other comments related to approval requirements	

Timelines	
FPI	Approximate date:
LPO	Approximate date:
Abstract or Manuscript Journal Submission or CSR	Approximate target month/year:

For retrospective or in vitro studies, summarize timelines	

Study Synopsis

Requestor must either attach Study Synopsis or, to the extent relevant, add the details in text form below.

See details below

See attached Synopsis

- Background, study rationale and unmet medical need
- Study population (detailed description of therapeutic area, patient type, setting, type of procedure if applicable, etc.)
- Hypothesis
- Study objective(s) (list as many as apply)
- Timelines (including all phases of a multi-phase study)
- Methodology/sequence of procedure
  - Screening period (if retrospective/prospective data evaluation, describe the process for screening charts for eligibility)
  - Treatment period (if using drug on-formulary for a retrospective/prospective data evaluation, please specify standard of care followed)
  - Follow-up period (if retrospective/prospective data evaluation, specify any part of patient care post-treatment or procedure for which data will be collected from the charts, including in a post-op area or post-48 hours, etc.)
- Clinical laboratory or other assessments
- Brief description of any disease state or quality of life measures that will be measured
- Inclusion and exclusion criteria
- Melinta product (dose and administration)
- Duration of treatment
- Reference therapy (dose and administration)
- Concomitant and prohibited medications
- Outcomes/endpoints (primary, secondary, exploratory)
- Statistical analyses/assumptions
- Schedule of assessments
- Flow diagram (if available)

Schedule of Assessment *(optional if not applicable)*
Define treatment period windows, if applicable.
Do not use Day Zero; Day -1 = pre-randomization and Day 1 = randomization.

Study Assessment	
Informed Consent	

Medical History	
Initiation of Study Drug Administration/Device Use	
Concomitant Medications	
Adverse Event Reporting	
Serious Adverse Event Reporting	
Type of Support Requested	
Financial	Are funds being requested from Melinta for a research grant? ◯ No ◯ Yes * Total amount requested:
	*If 'Yes', please attach an itemized budget showing the general breakdown of costs adding to the total requested above. ☐ Budget attached Budget version date:

	*If yes, please confirm if funding has been or will be requested from other manufacturers or funding companies or organizations (including NIH)? ◯ No ◯ Yes * Total amount requested:
Study Drug/Device Supply	To be provided by Melinta? ◯ No ◯ Yes
	Comments: Describe the plans/process for supplying drug and/or device to site(s).
Melinta Clinical Supplies Support	◯ No ◯ Yes
	*If 'Yes', please describe the type of support requested.
Statistical/Analytical Support	◯ No ◯ Yes
	*If 'Yes', please describe the type of support requested.
Data Management Support	◯ No ◯ Yes
	*If 'Yes', please describe the type of support requested.
Clinical Operations Support	◯ No ◯ Yes
	*If 'Yes', please describe the type of support requested (e.g. Internal CTAs, CRAs. Project Managers, etc.).
Safety Reporting Support	◯ No ◯ Yes
	*If 'Yes', please describe the type of support requested.

Post Approval Research & Development

Grant Application

Publications Support	◯ No ◯ Yes
	*If 'Yes', please describe the type of support requested.
Other Support	◯ No ◯ Yes
	*If 'Yes', please describe the type of support requested.